Clinical Considerations in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck - a podcast by ReachMD

CME credits: 0.25

Valid until: 30-06-2021

Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-immunotherapy-management-recurrentmetastatic-squamous-cell-carcinoma-head-and-neck/11576/

Squamous cell carcinoma of the head and neck is one of the most common cancers worldwide, with over 500,000 new cases and 380,000 deaths annually. In this regard, the poor outcomes associated with recurrent/metastatic squamous cell carcinoma of the head and neck represent a significant unmet medical need. For these patients, first-line pharmacologic therapy includes chemotherapy, targeted therapies, and immunotherapy, often in combination. Nonetheless, treatment selection is widely recognized as difficult due to complex patient and disease factors.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD